Now showing 1 - 5 of 5
No Thumbnail Available
Publication

In Vitro Evidence of Selective Pro-Apoptotic Action of the Pure Cannabidiol and Cannabidiol-Rich Extract

2023, Śledziński, Paweł, Nowak-Terpiłowska, Agnieszka Magdalena, Rzymski, Piotr, Słomski, Ryszard, Zeyland, Joanna

Plant cannabinoids, secondary metabolites of species belonging to the Cannabis genus, can mimic the endocannabinoids’ action and exert biological effects. Considering the contribution of the endocannabinoid system in cell cycle and apoptotic regulation, there is an interest in exploring the potential anti-cancer activities of natural and synthetic cannabinoids. Cannabidiol (CBD), an abundant plant cannabinoid, reveals a low affinity to cannabinoid receptors and, contrary to various cannabinoids, lacks psychoactive action. Here, we present the in vitro assessment of the pro-apoptototic potential of CBD-rich extracts of Cannabis sativa L. (eCBD) compared to purified CBD (pCBD). As demonstrated, both eCBD and pCBD decreased the viability of breast cancer cell line MDA-MB-231 and human prostate cancer cell line PC-3 in a concentration-dependent fashion. Endoplasmic reticulum stress-related apoptosis and morphological changes were induced only in low-serum conditions. Moreover, the effects of eCDB and pCDB were also assessed in non-malignant cell lines (MCF-10A and PNT2) with no alterations of viability noted, ultimately suggesting a selective action of CBD in tumor cells. The results suggest the possible involvement of reactive oxygen species in the response mechanism to eCBD and pCBD, but no clear pattern was observed. We also demonstrated significant changes in gene expression involved in apoptosis and cell cycle control upon extract treatment. Altogether, our study shows the potential of eCBD and pCBD as novel pro-apoptototic agents that can be considered promising in future preclinical and clinical testing.

No Thumbnail Available
Publication

Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review

2023, Zielińska, Aleksandra, Eder, Piotr, Karczewski, Jacek, Szalata, Marlena, Hryhorowicz, Szymon, Wielgus, Karolina, Szalata, Milena, Dobrowolska, Agnieszka, Atanasov, Atanas G., Słomski, Ryszard, Souto, Eliana B.

Commonly used clinical strategies against coronavirus disease 19 (COVID-19), including the potential role of monoclonal antibodies for site-specific targeted drug delivery, are discussed here. Solid lipid nanoparticles (SLN) tailored with tocilizumab (TCZ) and loading cannabidiol (CBD) are proposed for the treatment of COVID-19 by oral route. TCZ, as a humanized IgG1 monoclonal antibody and an interleukin-6 (IL-6) receptor agonist, can attenuate cytokine storm in patients infected with SARS-CoV-2. CBD (an anti-inflammatory cannabinoid and TCZ agonist) alleviates anxiety, schizophrenia, and depression. CBD, obtained from Cannabis sativa L., is known to modulate gene expression and inflammation and also shows anti-cancer and anti-inflammatory properties. It has also been recognized to modulate angiotensin-converting enzyme II (ACE2) expression in SARS-CoV-2 target tissues. It has already been proven that immunosuppressive drugs targeting the IL-6 receptor may ameliorate lethal inflammatory responses in COVID-19 patients. TCZ, as an immunosuppressive drug, is mainly used to treat rheumatoid arthritis, although several attempts have been made to use it in the active hyperinflammatory phase of COVID-19, with promising outcomes. TCZ is currently administered intravenously. It this review, we discuss the potential advances on the use of SLN for oral administration of TCZ-tailored CBD-loaded SLN, as an innovative platform for managing SARS-CoV-2 and related infections.

No Thumbnail Available
Publication

History of Biological Databases, Their Importance, and Existence in Modern Scientific and Policy Context

2025, Danielewski, Mikołaj, Szalata, Marlena, Nowak, Jan Krzysztof, Walkowiak, Jarosław, Słomski, Ryszard, Wielgus, Karolina

No Thumbnail Available
Publication

The Relative Abundances of Human Leukocyte Antigen-E, α-Galactosidase A and α-Gal Antigenic Determinants Are Biased by Trichostatin A-Dependent Epigenetic Transformation of Triple-Transgenic Pig-Derived Dermal Fibroblast Cells

2022, Samiec, Marcin, Wiater, Jerzy, Wartalski, Kamil, Skrzyszowska, Maria, Trzcińska, Monika, Lipiński, Daniel, Jura, Jacek, Smorąg, Zdzisław, Słomski, Ryszard, Duda, Małgorzata

The present study sought to establish the mitotically stable adult cutaneous fibroblast cell (ACFC) lines stemming from hFUT2×hGLA×HLA-E triple-transgenic pigs followed by trichostatin A (TSA)-assisted epigenetically modulating the reprogrammability of the transgenes permanently incorporated into the host genome and subsequent comprehensive analysis of molecular signatures related to proteomically profiling the generated ACFC lines. The results of Western blot and immunofluorescence analyses have proved that the profiles of relative abundance (RA) noticed for both recombinant human α-galactosidase A (rhα-Gal A) and human leukocyte antigen-E (HLA-E) underwent significant upregulations in tri-transgenic (3×TG) ACFCs subjected to TSA-mediated epigenetic transformation as compared to not only their TSA-unexposed counterparts but also TSA-treated and untreated non-transgenic (nTG) cells. The RT-qPCR-based analysis of porcine tri-genetically engineered ACFCs revealed stable expression of mRNA fractions transcribed from hFUT2, hGLA and HLA-E transgenes as compared to a lack of such transcriptional activities in non-transgenic ACFC variants. Furthermore, although TSA-based epigenomic modulation has given rise to a remarkable increase in the expression levels of Galα1→3Gal (α-Gal) epitopes that have been determined by lectin blotting analysis, their semi-quantitative profiles have dwindled profoundly in both TSA-exposed and unexposed 3×TG ACFCs as compared to their nTG counterparts. In conclusion, thoroughly exploring proteomic signatures in such epigenetically modulated ex vivo models devised on hFUT2×hGLA×HLA-E triple-transgenic ACFCs that display augmented reprogrammability of translational activities of two mRNA transcripts coding for rhα-Gal A and HLA-E proteins might provide a completely novel and powerful research tool for the panel of further studies. The objective of these future studies should be to multiply the tri-transgenic pigs with the aid of somatic cell nuclear transfer (SCNT)-based cloning for the purposes of both xenografting the porcine cutaneous bioprostheses and dermoplasty-mediated surgical treatments in human patients.

No Thumbnail Available
Publication

Rocznica odkrycia struktury DNA - nowe wyzwania dla medycyny

2023, Słomski, Ryszard, Wielgus, Karolina, Danielewski, Mikołaj, Szalata, Milena, Dreger, Mariola, Ożarowski, Marcin, Szalata, Marlena

Odkrycie DNA i poznanie jego struktury miało duże znaczenie zarówno na polu naukowym jak i w życiu codziennym. Rozpoznanie DNA jako związku stanowiącego nośnik informacji genetycznej pozwoliło na rozwój genetyki oraz opracowanie metod genetyki molekularnej. Znalazły one zastosowanie m. in. w medycynie, genetyce sądowej i kryminalistyce, diagnostyce molekularnej chorób genetycznych, pozyskiwaniu substancji bioaktywnych z zastosowaniem biotechnologii roślin, analizie archiwalnego DNA (aDNA), innowacyjnej technologii wykorzystania tkanek transgenicznych zwierząt dla celów biomedycznych, transgenicznych zwierzętach jako bioreaktorach oraz zastosowania organizmów modyfikowanych do prewencji chorób. W kwestii zdrowia, analizy DNA pozwoliły na wykrycie podłoża chorób genetycznych, a także przyczyniły się do poznania mechanizmów prowadzących do ich rozwoju. Techniki genetyki molekularnej znacząco ułatwiają i czynią bardziej dokładnym analizy pokrewieństwa i ocenę przynależności śladów biologicznych pozostawionych na miejscu zbrodni. Stale polepszający się warsztat metod analiz DNA umożliwił też postawienie kolejnego kroku milowego w nauce w postaci opracowania technik sekwencjonowania i poznania genomów człowieka oraz wielu innych organizmów. Z kolei opanowanie informacji genomowej dało możliwość produkcji wielu substancji biologicznie aktywnych na skalę przemysłową.